Vaxcyte, Inc. - Common Stock (NQ:PCVX)

56.48 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗

March 15, 2025

Via The Motley Fool

Topics Stocks

Are Small-Cap Stocks A Buy After Russell 2000 Correction? ↗

March 06, 2025

Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.

Via Benzinga

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 25, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

What's Driving the Market Sentiment Around Vaxcyte? ↗

February 25, 2025

Via Benzinga

Earnings Scheduled For February 25, 2025 ↗

February 25, 2025

Via Benzinga

(PCVX) - Analyzing Vaxcyte's Short Interest ↗

December 16, 2024

Via Benzinga

(PCVX) - Analyzing Vaxcyte's Short Interest ↗

November 28, 2024

Via Benzinga

Peering Into Vaxcyte's Recent Short Interest ↗

October 30, 2024

Via Benzinga

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

February 12, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗

February 12, 2025

The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Via Investor's Business Daily

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

February 05, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

January 30, 2025

From Vaxcyte, Inc.

Via GlobeNewswire

Peering Into Vaxcyte's Recent Short Interest ↗

August 27, 2024

Via Benzinga

1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank ↗

December 17, 2024

Via The Motley Fool

Topics Stocks

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

December 03, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst ↗

November 20, 2024

Via The Motley Fool

Topics Stocks

Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers ↗

November 17, 2024

10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio.

Via Benzinga

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

November 12, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

November 05, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

September 11, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 06, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

September 04, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

September 03, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗

September 03, 2024

Via Benzinga

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 03, 2024

Via Benzinga

Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher ↗

September 03, 2024

Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...

Via Benzinga

Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market ↗

September 03, 2024

The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.

Via Investor's Business Daily

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

September 03, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

September 02, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

August 06, 2024

From Vaxcyte, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.